Targeting lactylation of critical drivers in neuroendocrine prostate cancer for therapy

Active Grant Awarded

Award ID
R37CA311186
Recipient
Awarding agency
Obligated
$453,367

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date 3% complete
Place of performance
Lexington, KY 40506, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded The University of Kentucky Research Foundation $453,367 on September 23, 2026, as a grant under the Cancer Treatment Research program (CFDA 93.395). The award funds research into how lysine lactylation of the lineage-defining factors FOXA2 and INSM1 drives neuroendocrine prostate cancer progression and resistance to androgen receptor signaling inhibitors such as enzalutamide. The work pursues three specific aims: defining the functional significance of FOXA2 lactylation, determining the role of INSM1 lactylation in maintaining neuroendocrine characteristics, and evaluating whether targeting lactylation of both factors can prevent lineage plasticity-driven progression. Mouse models, including xenograft, allograft, and prostate regeneration systems, are used to evaluate progression and therapeutic response in vivo. Place of performance is Lexington, KY 40506, and the ultimate completion date is August 31, 2031.

Description

Abstract
Resistance to next-generation androgen receptor signaling inhibitors (ARSIS), such as enzalutamide (ENZ), remains a major clinical challenge in the treatment of metastatic castration-resistant prostate cancer (CRPC). A subset of these resistant tumors undergo lineage plasticity, transitioning into neuroendocrine prostate cancer (NEPC)-a highly aggressive, androgen receptor (AR)-independent variant characterized by poor prognosis and lack of effective therapies. NEPC emergence represents a critical barrier to durable responses in advanced prostate cancer, highlighting an urgent need to elucidate the molecular mechanisms driving treatment resistance and lineage plasticity. Our preliminary data demonstrate that the neuroendocrine lineage-defining factors FOXA2 and INSM1 undergo lysine lactylation, which enhances their protein stability and transcriptional activity. We hypothesize that lysine lactylation of these factors reinforces the NEPC phenotype and contributes to resistance against AR-targeted therapies. The overall objective of this proposal is to define the functional role of FOXA2 and INSM1 lactylation in NEPC progression and determine whether disrupting this regulatory mechanism can prevent or reverse lineage plasticity-driven therapeutic resistance. This hypothesis will be tested through the following specific aims: 1) elucidate the functional significance of FOXA2 lactylation in NEPC progression. 2) determine the role of INSM1 lactylation in maintaining NEPC characteristics.3) evaluate whether targeting lactylation of FOXA2 and INSM1 can prevent lineage plasticity-driven NEPC progression and serve as a therapeutic strategy. Mouse models are essential to evaluate NEPC progression, lineage plasticity, and therapeutic response in an in vivo setting that cannot be fully recapitulated in vitro. Established xenograft, allograft, prostate regeneration, and genetically engineered mouse models will be used to validate therapeutic efficacy and disease progression before clinical translation. Successful completion of this project will uncover a novel mechanism of therapy resistance in prostate cancer, define the role of post-translational regulation in lineage plasticity, and establish a foundation for therapeutic strategies aimed at preventing or reversing NEPC. These findings have the potential to transform the clinical management of therapy-resistant prostate cancer.

Quick answers

Who received award R37CA311186?

R37CA311186 was awarded to The University Of Kentucky Research Foundation by National Cancer Institute (National Institutes of Health) on September 23, 2026.

How much is award R37CA311186 worth?

$453,367 has been obligated on R37CA311186.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award